Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04274166
Other study ID # IRB00063109
Secondary ID Huang_IIT_CAIN45
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date May 2021
Est. completion date April 2022

Study information

Verified date May 2021
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to find out what effects (good and bad) secukinumab has on the subject and their pyoderma gangrenosum. Secukinumab is a type of medicine called human monoclonal antibodies. Monoclonal antibodies are proteins that recognize and attach to other specific proteins (in this case, immune system hormones called "cytokines") that your body produces. The cytokine (a "messenger" protein in the body) that secukinumab binds to and reduces the activity of is a naturally occurring cytokine called interleukin-17A (IL-17A). IL-17A is believed to be partly responsible for inflammation (pain, swelling, redness), and researchers believe that IL-17A may cause symptoms PG.


Description:

This is a prospective, single center, Phase IIa study of secukinumab in the treatment of subjects diagnosed with PG. Subjects will be evaluated at Screening, Baseline (week 0), Week 1, Week 2, Week 3, Week 4, and then every 4 weeks for 24 weeks. The total duration of treatment is up to 20 weeks. Subjects may be treated for shorter durations if the lesions clear prior to week 20. Subjects will have a follow-up visit at 24 weeks, or 4 weeks after the last dose of study drug. Subjects will also have standard of care wound dressings done at each visit. Subjects will be given 300 mg of secukinumab SQ at week 0, 1, 2, 3, and 4, followed by injections every 4 weeks, for up to 20 weeks. Subjects may receive a dose increase at week 16 (if there is not at least a 25% reduction in target lesion size) to 300 mg every 2 weeks. - Complete Blood Count (CBC), Comprehensive Metabolic panel (CMP), C- reactive protein (CRP), Erythrocyte sedimentation rate (ESR), Hepatitis panel, HIV test, Pregnancy test, and QuantiFERON gold TB test will be performed at screening. (Appendix 6) - CBC, CMP, CRP, ESR will be performed at week 8 and week 20. - Pain rating by Likert scale (A 10-point scale to rate the level of pain - Appendix 2), an Investigator Global Assessment (IGA) (Appendix 3), Subject Global Assessment (SGA) (Appendix 3), and Ulcer Lesion Assessment (Appendix 5) will be done at Screening, Baseline, and at Weeks 2, 4, 8, 12, 16, 20, and 24. - Lesion photography will be done at Screening and all visits. - Infection and adverse event assessments and concomitant medication assessments will be performed at each visit. - Quality of life will be measured with the Dermatology Life Quality Index (DLQI) at Baseline and Week 20 (Appendix 4).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2022
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Must give written informed consent. 2. Has a diagnosis of pyoderma gangrenosum, as determined by the investigator based on the following diagnostic criteria4: a. Diagnosis requires both major criteria and at least two minor criteria i. Major criteria 1. Rapid progression of a painful, necrolytic cutaneous ulcer with an irregular, violaceous, and undermined border 2. Other causes of cutaneous ulceration have been excluded ii. Minor criteria 1. History suggestive of pathergy or clinical finding of cribriform scarring 2. Systemic diseases associated with PG 3. Histopathologic findings (sterile dermal neutrophilia, ± mixed inflammation, ± lymphocytic vasculitis) 4. Treatment response (rapid response to systemic steroid treatment) 3. PG global assessment of moderate to severe, with at least one ulcer measuring at least 3 cm in diameter. 4. 18 years of age or greater. 5. Must require systemic therapy for their pyoderma gangrenosum, as determined by the investigator prior to Baseline. Currently prescribed low-dose corticosteroids (= 10 mg/day), and other medications within one week prior to investigational drug administration, may be continued with no change in dose or frequency during the study. Exclusion Criteria: 1. Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded. 2. Current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy (participation in registry-type studies is allowed). 3. Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within the 3 months prior to the first dose of investigational drug. 4. Treatment with another investigational drug or approved therapy for investigational use within 28 days prior to investigational drug administration. 5. Treatment with high dose (>10 mg/day) systemic steroids (prednisone) within one week prior to investigational drug administration. Treatment with cyclosporine, thalidomide, methotrexate, mycophenolate mofetil, azathioprine, or other systemic immunosuppressant agents within the 14 days prior to investigational drug administration (requirement of a 2-week washout). 6. Known HIV+, known viral hepatitis infection, known tuberculosis infection. 7. Any subject with a current or history of a malignancy in the last five years (excluding treated basal cell carcinoma). 8. Clinically significant abnormal laboratory measures at screening. 9. Known Irritable Bowel Disease-associated PG

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
secukinumab 150 mg (2 injections per dose
secukinumab 150 mg (2 injections per dose

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Health Sciences Novartis

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Screening visit
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Screening visit to Baseline visit.
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Baseline visit to Week 2.
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from week 2 to week 4.
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 4 to week 8.
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 8 to week 12.
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 12 to week 16.
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 16 to week 20.
Primary Efficacy - Investigator Global Assessment (IGA) Investigator Global Assessment (IGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 20 to week 24.
Primary Efficacy - Subject Global Assessment (SGA) Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Baseline.
Primary Efficacy - Subject Global Assessment (SGA) Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Baseline to week 2.
Primary Efficacy - Subject Global Assessment (SGA) Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 2 to Week 4.
Primary Efficacy - Subject Global Assessment (SGA) Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 4 to Week 8. .
Primary Efficacy - Subject Global Assessment (SGA) Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 8 to Week 12.
Primary Efficacy - Subject Global Assessment (SGA) Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 12 to Week 16.
Primary Efficacy - Subject Global Assessment (SGA) Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 16 to Week 20.
Primary Efficacy - Subject Global Assessment (SGA) Subject Global Assessment (SGA) as measured by a 7 point scale anchored by 'Completely Clear" and "Worse" Change from Week 20 to Week 24.
Primary Efficacy - Ulcer Lesion Assessment PG Target Lesion Number of subjects achieving 50% improvement in PG lesion size Change from Screening visit, Baseline, and at Weeks 2, 4, 8, 12, 16, 20, and 24.
Primary Efficacy - Ulcer Lesion Assessment PG Target Lesion Number of subjects achieving resolution of inflammation with an erythema score of 0 and a border elevation of 0 on five point scales of none to very severe Change from Screening visit, Baseline, and at Weeks 2, 4, 8, 12, 16, 20, and 24.
See also
  Status Clinical Trial Phase
Recruiting NCT06092216 - Spesolimab in Pyoderma Gangrenosum Phase 2
Completed NCT03311464 - A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan Phase 3
Recruiting NCT04901325 - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Phase 2
Completed NCT00791557 - Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease N/A
Terminated NCT02318914 - A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Phase 3
Terminated NCT02315417 - An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Phase 3
Completed NCT03137160 - An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT05984654 - Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum N/A
Completed NCT04895566 - Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma Early Phase 1
Completed NCT01882504 - Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Withdrawn NCT00730717 - Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT03971643 - Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT04792957 - JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Not yet recruiting NCT05821374 - Deucravacitinib in PG Early Phase 1
Terminated NCT03072953 - Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Phase 2
Recruiting NCT05120726 - A Novel Therapeutic Treatment of Pyoderma Gangrenosum Phase 4
Withdrawn NCT00690846 - Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT01965613 - A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Phase 2
Recruiting NCT01952275 - Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases N/A
Completed NCT01302795 - Canakinumab for Pyoderma Gangrenosum Phase 2